Drug intelligence / Profile preview

Kangfu

Development stage: Phase 4
Lead developer: 安徽安科余良卿药业
Administration: Oral, Rectal, Vaginal, Topical

Overview

The term 'Kangfu' is non-specific and appears in the names of several distinct products. These include traditional Chinese medicines or polybotanical dietary supplements such as Shenyan Kangfu tablets (SYKFT) and Kang-fu-ling (KFL), which have been investigated for conditions like diabetic nephropathy, neuroprotection, and myocardial injury. It also appears in the name of a pharmaceutical product, Kangfu Anti-inflammatory Suppository. Due to the ambiguity, specific details regarding mechanism of action, developers, and indications vary significantly across these different products.

Beyond the preview

Go deeper on Kangfu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kangfu.

Explore the full profile